SCHEMBL4770029

SCHEMBL4770029

COC(=O)C(Cc1cnc(Nc2ccccc2)nc1NCC1CC1)c1ccc(OC)cc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SYK P43405 7/20 0.44
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
VCP P55072 1/20 0.42
MAPK9 P45984 3/20 0.41
MAPK10 P53779 1/20 0.41
CHEK1 O14757 1/20 0.41
NTRK2 Q16620 1/20 0.41
PRKCQ Q04759 1/20 0.41
FLT3 P36888 1/20 0.39
MAPK8 P45983 1/20 0.39
JAK2 O60674 1/20 0.39
JAK3 P52333 1/20 0.39
BTK Q06187 1/20 0.39
SIRT5 Q9NXA8 1/20 0.39
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4765277 0.94 SYK (0.44) SYKMAOAMAOBVCPMAPK9
SCHEMBL4764815 0.88 CHEK1 (0.49) SYKMAOAMAOBMAPK9MAPK10
SCHEMBL4767407 0.87 CHEK1 (0.43) SYKMAOAMAOBMAPK9MAPK10
SCHEMBL4766654 0.82 CHEK1 (0.46) SYKMAPK9MAPK10CHEK1NTRK2
SCHEMBL4769944 0.82 MAPK9 (0.44) SYKMAOAMAOBMAPK9MAPK10
SCHEMBL4774864 0.81 CHEK1 (0.50) SYKMAPK9MAPK10CHEK1NTRK2
SCHEMBL4769925 0.81 AURKA (0.48) SYKMAPK9NTRK2FLT3MAPK8
SCHEMBL4765275 0.80 CHEK1 (0.43) SYKMAOAMAOBMAPK9MAPK10
SCHEMBL4765299 0.80 SYK (0.49) SYKMAPK9CHEK1NTRK2MAPK8
SCHEMBL4771576 0.80 EGFR (0.47) SYKMAPK9NTRK2FLT3MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581531-B1 PYRIDINO¬2,3-D PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS HOFFMANN LA ROCHE (CH) 2008-02-27 EP claimed
US-7098332-B2 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones HOFFMANN-LA ROCHE INC. (US) 2006-08-29 US claimed
EP-1581531-A1 PYRIDINO[2,3-D]PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS F. Hoffmann-La Roche AG (CH) 2005-10-05 EP claimed
WO-2004056822-A1 PYRIDINO `2, 3-D! PYRIMIDINE DERIVATIVES AS SELECTIVE KDR AND FGFR INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-08 WO claimed
US-20040122029-A1 Novel dihydropyridinone compounds LIU JIN-JUN (US) 2004-06-24 US claimed
EP-1581531-B1 PYRIDINO¬2,3-D PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS HOFFMANN LA ROCHE (CH) 2008-02-27 EP disclosed
US-7098332-B2 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones HOFFMANN-LA ROCHE INC. (US) 2006-08-29 US disclosed
EP-1581531-A1 PYRIDINO[2,3-D]PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS F. Hoffmann-La Roche AG (CH) 2005-10-05 EP disclosed
WO-2004056822-A1 PYRIDINO `2, 3-D! PYRIMIDINE DERIVATIVES AS SELECTIVE KDR AND FGFR INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-08 WO disclosed
US-20040122029-A1 Novel dihydropyridinone compounds LIU JIN-JUN (US) 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122029-A1 Novel dihydropyridinone compounds FGFR1, FGFR3, FGFR4 SYK 187/4885MAOA 3592/4885MAOB 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.